The Norwegian Nucleoside Analogue Stop Study

Exclusion Criteria

• •A history of decompensated liver disease, either by clinical signs (ascites, encephalopathy, portal hypertension, jaundice) or suggestive laboratory results (total bilirubin \>38 umol/L, INR \>1.5, platelets \<75,000/mm3, serum albumin \<30 g/L).
• •Any previous diagnosis of cirrhosis, either by liver biopsy (Metavir score F4) or elastography (Fibroscan \>12 kPa). Elastography results with concomitant ALT \>200 U/L are not considered.
• •Previous hepatocellular carcinoma (HCC).
• •Co-infections with HIV, hepatitis C or hepatitis D.
• •Other disease or medication that can interfere with the study (e.g. ongoing alcohol or illicit drug abuse, immunosuppressive medication, other active liver disease, or any other condition which in the opinion of the physician is incompatible with participation)